Full Breakdown
Review Questions Efficacy of Alzheimer’s Drugs Targeting Amyloid
4/16/2026, 6:08:09 AM
Overview of the Findings
A recent Cochrane review has concluded that anti-amyloid drugs, which have been promoted as significant advancements in Alzheimer’s treatment, do not provide meaningful benefits to patients. The analysis, which synthesized data from 17 clinical trials involving over 20,000 participants with mild cognitive impairment or mild dementia, found that the drugs had “trivial” effects on cognitive function and dementia severity over an 18-month period. Notably, the review highlighted that these treatments, including lecanemab by Eisai and donanemab by Eli Lilly, were associated with increased risks of brain swelling and bleeding.
Methodology and Criticism
The review's methodology has faced scrutiny, particularly for combining results from both successful and failed drug trials. Critics, including Charles Marshall from Queen Mary University, argue that this approach skews the findings, leading to an underestimation of the potential benefits of newer drugs. Dr. Susan Kohlhaas from Alzheimer’s Research UK emphasized that different anti-amyloid treatments may have distinct mechanisms and effects, suggesting that the review unfairly generalized the efficacy of an entire class of drugs.
Perspectives from Experts
Edo Richard, a co-author of the review, stated that the evidence indicates no clinically meaningful effect from the drugs, despite earlier trials showing statistically significant results. He noted that the burdensome nature of the treatments, which require frequent clinic visits and monitoring, further complicates their utility for patients. Conversely, some researchers defend the review's methodology, arguing that including both effective and ineffective treatments is essential for a comprehensive understanding of the drugs' impacts.
Official Statements & Responses
The findings have prompted varied responses from stakeholders in the medical community. A spokesperson for Eli Lilly criticized the review as “inherently flawed,” asserting that it conflates failed medications with those that have received regulatory approval. Eisai also contended that the analysis is scientifically unsound, arguing that it fails to recognize the clinical benefits of their approved therapies. Meanwhile, the National Institute for Health and Care Excellence (NICE) is reconsidering its previous decision not to fund these drugs in the UK, following appeals from the manufacturers.
Broader Implications
The review raises significant questions about the future of Alzheimer’s research and treatment strategies. Experts suggest that the focus on amyloid may have overshadowed other potential therapeutic avenues. As research evolves, there is a growing consensus that a broader range of biological targets should be explored to develop more effective treatments for Alzheimer’s disease.
Conflicting Reports & Gaps
While the Cochrane review presents a unified conclusion regarding the ineffectiveness of anti-amyloid drugs, dissenting voices within the scientific community highlight the need for nuanced interpretations. Some argue that the review's findings do not adequately represent the potential benefits of newer drugs like lecanemab and donanemab, which have been deemed to provide modest but meaningful benefits by regulatory bodies.
Verbatim Quotes
- “The sad truth is that even the best-performing drugs don’t do anything that’s clinically meaningful.” — Robert Howard, Professor of Old Age Psychiatry, UCL
- “paint an entire class of drugs with the same brush” — Dr. Susan Kohlhaas, Alzheimer’s Research UK
- “By mixing failed drugs with the only antibodies that have actually changed clinical practice, it turns therapeutic progress into statistical noise.” — Bart De Strooper, UK Dementia Research Institute
The ongoing debate surrounding the efficacy of anti-amyloid drugs underscores the complexities of Alzheimer’s treatment and the necessity for continued research in the field.
